###begin article-title 0
The Serum High-Sensitive C Reactive Protein and Homocysteine Levels to Evaluate the Prognosis of Acute Ischemic Stroke
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 1018 1019 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1086 1088 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1124 1126 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1165 1167 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1259 1261 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 1360 1361 1340 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
###xml 925 933 <span type="species:ncbi:9606">patients</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
###xml 1299 1307 <span type="species:ncbi:9606">patients</span>
###xml 1385 1393 <span type="species:ncbi:9606">patients</span>
###xml 1561 1569 <span type="species:ncbi:9606">patients</span>
Ischemic stroke is one of the most common causes of death worldwide and is most often caused by thrombotic processes. We investigated the changes in hsCRP and homocysteine levels, two of these risk factors, during the acute period of ischemic stroke and evaluated the relationship between these levels and the short-term prognosis. HsCRP and homocysteine levels were measured at the 2nd, 5th, and 10th days in forty patients admitted within second of an ischemic stroke. The clinical status of the patients was simultaneously evaluated with the Scandinavian stroke scale. The results were compared with 40 healthy control subjects whose age and sex were matched with the patients. The mean hsCRP levels of the patients were 9.4 +/- 7.0 mg/L on the 2nd day, 11.0 +/- 7.4 mg/L on the 5th day, and 9.2 +/- 7.0 mg/L on the 10th day. The mean hsCRP level of the control subjects was 1.7 +/- 2.9 mg/L. The mean hsCRP levels of the patients on the 2nd, 5th, and 10th days were significantly higher than the control subjects (P < .001). The patients' mean homocysteine levels were 40.6 +/- 9.6 mumol/L on the 2nd day, 21.7 +/- 11.1 mumol/L on the 5th day, and 20.7 +/- 9.2 mumol/L on the 10th day. The mean homocysteine level of the control subjects was 11.2 +/- 1.1 mumol/L. The homocysteine levels of the patients were higher than the control subjects at all times (P < .01). In conclusion, patients with stroke have a higher circulating serum hsCRP and homocysteine levels. Short-term unfavorable prognosis seems to be associated with elevated serum hsCRP levels in patients with stroke. Although serum homocysteine was found to be higher, homocysteine seems not related to prognosis.
###end p 2
###begin title 3
1. INTRODUCTION
###end title 3
###begin p 4
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Acute ischemic stroke develops as a result of a sudden interruption in the focal cerebral blood flow [1, 2]. The cause of the stroke is an embolic or thrombotic occlusion in 70-80% of patients with severe symptoms [3, 4].
###end p 4
###begin p 5
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
Recent research has shown that an inflammatory reaction is triggered within hours in the brain tissue injured by an ischemic stroke and continues in the days following the appearance of symptoms and that this reaction contributes to neuronal damage [5].
###end p 5
###begin p 6
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Increased CRP levels are accepted as a sensitive but nonspecific marker of the acute inflammatory response. CRP levels can increase 100 to 500 folds in acute inflammatory conditions [6]. Laboratory and experimental findings have shown that atherosclerosis is a reflection of a chronic inflammatory process in addition to lipid deposition [7, 8]. Inflammatory mechanisms have been known to play a role in all stages of atherosclerosis, from initiation to development [9-12].
###end p 6
###begin p 7
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 304 311 <span type="species:ncbi:9606">persons</span>
It has been reported that it is possible to use the increase in the concentration of acute phase reactants and especially the high sensitivity C-reactive protein (hsCRP) to help predict future cardiovascular morbidity [8, 12-14]. Various prospective studies have found initial CRP levels to be higher in persons who develop stroke, ischemic heart disease, and peripheral artery disease [15-17].
###end p 7
###begin p 8
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
There is increasing evidence that mild hyperhomocysteinemia is an independent risk factor for atherosclerosis and atherothrombosis in the coronary, cerebral, and peripheral vascular structures [17-20].
###end p 8
###begin p 9
The aim of this study was to determine the acute course of hsCRP and homocysteine levels following a stroke and their association with the short-term prognosis. An increasing amount of evidence shows these substances to be risk factors for atherosclerosis and therefore ischemic stroke.
###end p 9
###begin title 10
2. MATERIAL AND METHOD
###end title 10
###begin p 11
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 458 465 <span type="species:ncbi:9606">patient</span>
###xml 477 484 <span type="species:ncbi:9606">patient</span>
A total of 40 patients whose age mean is 69 +/- 11 years presenting at the Firat University Medical Faculty Neurology Outpatients Department with a clinical picture of acute ischemic stroke within the first 2 days and admitted with a diagnosis of ischemic stroke were included in the study. The control group consisted of 40 healthy volunteers whose age mean is 70 +/- 9 years who did not have any defined illnesses and were matched for age and sex with the patient group. The patient and control group subjects were informed on the study, and written consent was obtained.
###end p 11
###begin p 12
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
A diagnosis of acute ischemic stroke was made following a full neurological evaluation including the use of neuroradiologic imaging such as CT and/or MRI in patients who had suffered an acute focal neurologic deficit for more than 24 hours and who did not have a cause other than cerebrovascular disease for this neurological deficit. The clinical status of the patients was evaluated with the Scandinavian stroke scale.
###end p 12
###begin p 13
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">Patients</span>
The medical history was obtained from the patients with particular attention to defined risk factors such as DM, smoking, and dyslipidemia. Physical and neurological examinations, CT and carotid-vertebral Doppler ultrasonograpy, and other routine laboratory analyses were carried out on all patients. Patients whose neurological symptoms improved within 24 hours, those receiving a diagnosis of hemorrhagic cerebrovascular disease following clinical and neuroradiologic evaluation and those who had previously suffered an ischemic stroke were not included in the study.
###end p 13
###begin p 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
Patients who had heart disease which could lead to cardioembolism such as atrial fibrillation or cardiac valve disease or thyroid or renal dysfunction or kidney failure, patients with local or systemic infection or those who had suffered an infection within the last month, and those with romatoid arthritis, osteoarthritis, or malignancy were not included in the study. The patients were asked about the usage of drugs such as vitamin combinations, methotrexate, tamoxifen, nitrous oxide anesthesia, or anticonvulsant drugs within the last month as these could influence homocysteine concentrations.
###end p 14
###begin p 15
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Venous blood samples for hsCRP and homocysteine measurements were obtained from the patients on 2nd, 5th, and 10th days. The serum was separated within the hour by centrifugation at 5000 rpm for 10 minutes. The separated sera were kept at -70degreesC until the laboratory evaluation. The control group provided a single venous blood sample.
###end p 15
###begin p 16
###xml 462 464 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 551 553 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 592 594 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
HsCRP was studied by the nefelometric method with an hsCRP kit (Dade Behring. USA) on the Behring Nephelometer 100 Analyzer and the results were expressed as mg/L. The limit of detection for CRP is 0.175 mg/L. The homocysteine level was studied with fluorescent detectors using the "high performance liquid chromatography (HPLC)" method with the Clin Rep kit HPLC, Recipechemicals-Instruments GmbH Labortechnik, Munich, Germany and the results were expressed as mumol/L. The determination of homocysteine in plasma is linear within a range of 1 to100 mumol/L and lower detection limit is 0.5 mumol/L.
###end p 16
###begin p 17
###xml 267 268 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The results of the groups were expressed as mean +/- standard deviation. The data produced during the study were evaluated on the SPSS 12.0 package software program using the Mann-Whitney U test, chi square test, Spearman correlation test, and Kruscal-Wallis test. A P value < .05 was considered significant.
###end p 17
###begin title 18
3. RESULTS
###end title 18
###begin p 19
###xml 323 324 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 463 464 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 560 561 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 616 623 610 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
Seven of the 40 patients died during the study period. Fifteen of the remaining 33 patients were able to walk independently at the end of the study period (group A) while 18 patients could not (group B). The 2nd day's SSS scores of died patients (13.7 +/- 5.7) were significantly lower than living patients (28.3 +/- 14.7, P < .05). SSS scores of patients increased gradually and the highest mean scores were determined at the 10th day of illness (36.0 +/- 16.0, P < .05). The increase in the SSS score among the evaluation days was statistically significant (P < .05). The mean SSS scores of patients were shown in Table 1.
###end p 19
###begin p 20
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The hsCRP levels following the stroke increased from the 2nd day to the 5th day in a significant manner (P < .05) and then decreased on the 10th day again in a significant manner (P < .05). There was no significant difference between the hsCRP levels in the 2nd day and on the 10th day for hsCRP levels.
###end p 20
###begin p 21
###xml 412 413 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 639 640 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 691 698 681 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 9 16 <span type="species:ncbi:9606">patient</span>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
When the patient's clinical status according to the 2nd day hsCRP levels was checked, the dying patients had the highest level (14.7 +/- 7.9 mg/L) while patients who could walk had the lowest level (7.1 +/- 3.9 mg/L) with patients who could not walk having values between these two levels (9.2 +/- 8.2 mg/L). The hsCRP level was significantly lower in the patients who could walk compared to the dying patients (P < .005). When the 2nd day's hsCRP levels of the dying and surviving patients were compared, the values were significantly higher in the dying patients (14.7 +/- 7.9 mg/L) compared to the surviving patients (8.2 +/- 6.6 mg/L, P < .05). The mean hsCRP concentration was shown in Table 2.
###end p 21
###begin p 22
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 352 354 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 717 724 716 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 73 80 <span type="species:ncbi:9606">patient</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 295 302 <span type="species:ncbi:9606">patient</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
The difference between the three mean homocysteine concentrations of the patient group was not statistically significant (P > .05). There was no statistically significant difference between the mean homocysteine concentrations of the dying and surviving patients. It was found that 72.5% of the patient groups have a homocysteine levels higher than 15 mumol/L while it was higher only 25% of the control group and all of the three mean homocysteinemia concentration of the patients with ischemic stroke were significantly higher than in healthy control. There was no significant difference between the female and male patients for homocysteine and hsCRP levels. The mean hsCRP homocysteine concentration was shown in Table 3.
###end p 22
###begin p 23
No significant correlation was found between homocysteine and hsCRP levels.
###end p 23
###begin title 24
4. DISCUSSION
###end title 24
###begin p 25
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
The most important cause of ischemic strokes is atherothrombotic events. Atherosclerosis develops during a long asymptomatic period and the first sign of its existence is an acute event (MI, stroke) [11]. Laboratory and clinical evidence has shown that systemic inflammation plays a role in every stage from the beginning atherosclerosis to subendothelial lipid deposition [8, 11]. HsCRP is an indication of the inflammatory response to atherosclerosis. It is also a response to inflammation that developing during ischemic stroke as a result of tissue injury [21]. Beamer et al. [22] have reported that stroke patients without infection have increased levels of CRP. Experimental stroke studies have shown that secretion of inflammatory mediators as a direct response to cerebral injury starts within two hours of focal ischemia and that occurred anti-inflammatory treatment is also neuroprotective [23-25].
###end p 25
###begin p 26
###xml 13 15 13 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
Muir et al. [26] have shown that CRP levels within the first 72 hours following an acute ischemic stroke are an independent indicator for predicting survival. Our prospective study showed that the second day hsCRP levels of patients who died within the first 10 days were significantly higher than the surviving patients. It has been reported that a large infarcts and cortical involvement in patients had a higher CRP values than normal at the time of presentation [27]. The same report also suggests that the prognosis is worse in patients with increased CRP levels. Our finding that patients who could walk independently at the end of the study period have the lowest hsCRP value is also consisted these reports. The cause of the increased hsCRP in patients who died, and the lowest hsCRP levels in the walked group may be a indicator of the degree of underlying inflammation. Under the light of our observation and recent literature, our suggestion is that hsCRP may be a prognostic marker of the prognosis of these patients.
###end p 26
###begin p 27
###xml 102 104 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 433 435 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 437 439 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 490 492 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 46 53 <span type="species:ncbi:9606">patient</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
In this study, it was found that 72.5% of the patient group have a homocysteine levels higher than 15 mumol/L while it was higher only 25% of the control group and all of the three mean homocysteinemia concentration of the patients with ischemic stroke were significantly higher than in healthy control. Recent studies have shown that acute hyperhomocysteinemia leads to endothelial dysfunction, contributes to atheroma development [28, 29], and correlates with cerebral arterial stenosis [30].
###end p 27
###begin p 28
###xml 19 21 19 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
Meiklejohn et al. [31] reported that the homocysteine levels measured in patients with ischemic stroke and transient ischemic attack in the first 24 hours and after three months did not increase in the acute stage after the atherothrombotic stroke but increased during convalescence. The homocysteine concentrations of the patients were found to be significantly higher than the control group. They have explained this change in the homocysteine levels as due to an increase in the homocysteine level in the prestroke periods which then decrease in the acute phase for unknown reasons. They postulate that this may be a result of changes in the synthesis of plasma proteins in association with the acute phase response [31]. However, it is necessary to check homocysteine levels before and after the stroke to support this hypothesis and it is not possible to predict the development of stroke.
###end p 28
###begin p 29
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
There are several reports suggesting that mean homocysteine concentrations following a stroke are higher in the convalescent period than the acute stage, and mild hyperhomocysteinemia increased the unfavorable prognosis risk by 11.78 times [32-34]. It seems that increased homocysteine levels in these patients may be both a cause and also a result of this process due to acceleration of oxidative stress [32].
###end p 29
###begin p 30
###xml 347 355 <span type="species:ncbi:9606">Patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
In the view of the findings of the present study there was no significant increase in the homocysteine concentrations in the 10 days following a stroke. We conclude that homocysteine levels have a limited value for observation of severity of stroke. Although serum homocysteine was found to be higher, homocysteine seems not related to prognosis. Patients with stroke have a higher circulating serum hsCRP and homocysteine levels. Short term unfavorable prognosis seems to be associated with elevated serum hsCRP levels in patients with stroke and may also be able to predict progression of stroke.
###end p 30
###begin article-title 31
Factors determining the therapeutic window for stroke
###end article-title 31
###begin article-title 32
Which targets are relevant for therapy of acute ischemic stroke?
###end article-title 32
###begin article-title 33
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism
###end article-title 33
###begin article-title 34
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA acute stroke study group
###end article-title 34
###begin article-title 35
The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy
###end article-title 35
###begin article-title 36
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
###end article-title 36
###begin article-title 37
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
###end article-title 37
###begin article-title 38
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease
###end article-title 38
###begin article-title 39
Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study
###end article-title 39
###begin article-title 40
Inflammatory bio-markers and cardiovascular risk prediction
###end article-title 40
###begin article-title 41
Atherosclerosis-an inflammatory disease
###end article-title 41
###begin article-title 42
###xml 55 60 <span type="species:ncbi:9606">human</span>
Direct proinflammatory effect of C-reactive protein on human endothelial cells
###end article-title 42
###begin article-title 43
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
###end article-title 43
###begin article-title 44
###xml 63 71 <span type="species:ncbi:9606">patients</span>
High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease
###end article-title 44
###begin article-title 45
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
###end article-title 45
###begin article-title 46
C-reactive protein and risk of cardiovascular disease: evidence and clinical application
###end article-title 46
###begin article-title 47
Homocysteine and risk of recurrent stroke
###end article-title 47
###begin article-title 48
Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
###end article-title 48
###begin article-title 49
Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke
###end article-title 49
###begin article-title 50
Homocysteine, MTHFR 677C--> T polymorphism, and risk of ischemic stroke: results of a meta-analysis
###end article-title 50
###begin article-title 51
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome
###end article-title 51
###begin article-title 52
Interleukin-6 and interleukin-1 receptor antagonist in acute stroke
###end article-title 52
###begin article-title 53
Involvement of cytokines in acute neurodegeneration in the CNS
###end article-title 53
###begin article-title 54
###xml 135 139 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats
###end article-title 54
###begin article-title 55
###xml 72 76 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats
###end article-title 55
###begin article-title 56
C-reactive protein and outcome after ischemic stroke
###end article-title 56
###begin article-title 57
C-reactive protein in ischemic stroke: an independent prognostic factor
###end article-title 57
###begin article-title 58
Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy
###end article-title 58
###begin article-title 59
Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins
###end article-title 59
###begin article-title 60
Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis
###end article-title 60
###begin article-title 61
Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke
###end article-title 61
###begin article-title 62
Plasma homocysteine in the acute and convalescent phases after stroke
###end article-title 62
###begin article-title 63
Role of homocysteine in the acute phase of stroke
###end article-title 63
###begin article-title 64
Plasma homocysteine level and the course of ischemic stroke
###end article-title 64
###begin p 65
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
###xml 27 30 27 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF1"><sup>(a)</sup></xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Mean SSS scores of patients(a).
###end p 65
###begin p 66
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
###xml 33 34 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
(a)Mean +/- standard deviation, *P < .05.
###end p 66
###begin p 67
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
###xml 46 49 46 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF2"><sup>(a)</sup></xref>
Serum hsCRP levels of study and control groups(a).
###end p 67
###begin p 68
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
(a)Mean +/- standard deviation, NS: no significant.
###end p 68
###begin p 69
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
###xml 53 56 53 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF3"><sup>(a)</sup></xref>
Serum homocysteine levels of study and control groups(a).
###end p 69
###begin p 70
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
(a)Mean +/- standard deviation, NS: no significant.
###end p 70

